Ascentage Pharma Group International (AAPG) Cash & Equivalents (2023 - 2026)

Ascentage Pharma Group International's Cash & Equivalents history runs 4 years deep, the most recent figure standing at $348.3 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 180.1% year-over-year to $348.3 million; the TTM figure through Dec 2025 stood at $348.3 million (up 180.1% YoY), while the FY2025 annual figure was $812000.0, down 99.36% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $348.3 million, up from $231.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $348.3 million in Q4 2025, with the low at $3.4 million in Q4 2023.
• The 4-year median for Cash & Equivalents is $189.2 million (2022), against an average of $179.4 million.
• The sharpest annual moves came in 2023 and 2024: Cash & Equivalents sank 98.2% in 2023, then surged 3548.41% in 2024.
• Ascentage Pharma Group International's Cash & Equivalents stood at $189.2 million in 2022, then slumped by 98.2% to $3.4 million in 2023, then soared by 3548.41% to $124.3 million in 2024, then surged by 180.1% to $348.3 million in 2025.
• Business Quant data shows AAPG's Cash & Equivalents at $348.3 million in Q4 2025, $231.9 million in Q2 2025, and $124.3 million in Q4 2024.